All stock lists
Unlock the score
NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS)
NL · Delayed Price · Currency is USD
Healthcare · Biotechnology
19.60-0.11 (-0.56%)
Market cap
$2.29B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 9, 2021
Website
Insider Score
/ 100
NAMS Insider Score
NewAmsterdam Pharma Co N.V. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Financial Health Score
Fair
From NAMS’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $7.1M
- Net income
- -$259.5M
- Net margin
- -3644.2%
Leverage20 / 20
Little or no net debt.
- Total debt
- $82K
- Cash
- $424.2M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $659.2M
- Current liabilities
- $73.0M
- Current ratio
- 9.03
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$143.5M
- Free cash flow
- -$143.7M
- FCF margin
- -2018.3%
Dilution & runway12 / 20
Some dilution over the past year.
- Shares outstanding
- 123.4M
- Share growth (1y)
- 9.7%
- Cash runway
- 35 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NAMS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 3.70 M | 3.04 M | 32.00 K | 348.00 K | 19.14 M | 2.98 M |
| Revenue Growth (YoY) | -80.67 % | 2.08 % | -99.75 % | -98.80 % | 740.06 % | 112.56 % |
| Cost of Revenue | 0.00 | 500.00 K | 59.00 K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.70 M | 2.54 M | -27.00 K | 348.00 K | 19.14 M | 2.98 M |
| SG&A Expense | 26.89 M | 23.45 M | 27.36 M | 24.52 M | 27.26 M | 27.15 M |
| R&D Expense | 41.67 M | 37.51 M | 38.59 M | 30.97 M | 27.52 M | 44.75 M |
| Operating Expenses | 68.56 M | 60.96 M | 65.95 M | 55.49 M | 54.78 M | 71.90 M |
| Operating Income | -64.86 M | -58.42 M | -65.98 M | -55.14 M | -35.63 M | -68.92 M |
| Pretax Income | -64.14 M | -48.44 M | -74.92 M | -72.00 M | -17.36 M | -39.53 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -64.14 M | -48.44 M | -74.92 M | -72.00 M | -17.36 M | -39.53 M |
| EPS (Basic) | -0.52 | -0.40 | -0.65 | -0.61 | -0.15 | -0.34 |
| EPS (Diluted) | -0.52 | -0.40 | -0.65 | -0.61 | -0.15 | -0.34 |
| Shares Outstanding | 123.37 M | 121.10 M | 114.40 M | 119.00 M | 112.51 M | 116.12 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.